<DOC>
	<DOCNO>NCT02529449</DOCNO>
	<brief_summary>The objective study ass pharmacodynamics , pharmacokinetics , safety ASP1941 patient type 1 diabetes mellitus administer daily ( q.d . ) 2 week .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics , Safety ASP1941 Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>At time obtain informed consent : Subject diagnose type 1 diabetes mellitus treat insulin therapy least 52 week ( 364 day ) . Subject able admit site schedule . Subject able record Patient 's diary first study drug dose observation period day end post observation . At screen period : Subject HbA1c ( NGSP ) value 7.5 % 10.0 % . If subject HbA1c value 7.3 % 10.2 % ( reference range ) , HbA1c may remeasured within allowance range screen period . Remeasured HbA1c ( NGSP ) value adopt determination . Subject receive insulin therapy daily dos ( instructed doctor ) within ±20 % range least 12weeks ( 83days ) prior start screening . Subject fast serum Cpeptide level ≤0.5 ng/mL screen . Subject receive treatment complication ( except transient disease cold ) , investigator 's subinvestigator 's opinion , need change period start screen end treatment period . Subject body mass index ( BMI ) value 20.0 35.0 kg/m2 screening . At time obtain informed consent : Subject type 2 diabetes mellitus . Subject participate participate clinical study post marketing study another drug medical equipment within 12 week ( 84 day ) prior obtain inform consent . Subject receive ASP1941 ( ipragliflozin ) exception placebo . At screen period : Subject proliferative retinopathy ( subject stable condition photocoagulation etc . may enrol study ) . Subject develop hypoglycemia unawareness ( require help third person ) severe hypoglycemia ( diabetic coma , precoma , convulsion ) within 12 week ( 84 day ) prior start screening . Subject develop diabetic ketoacidosis within 12 week ( 84 day ) prior start screening . Subject chronic disease ( ) require continuous use corticosteroid immunosuppressant ( oral administration , injection , inhalation , suppository ) . Subject receive hypoglycemic agent ( ) insulin within 12 week ( 83 day ) prior start screening . Subject perioperative , severe infection serious injury . Subject whose serum creatinine value exceed upper limit normal range screening . Subject urinary albumin/urinary creatinine ratio &gt; 300 mg/g urinalysis screening . Subject history clinically significant renal disease ( ) renovascular occlusive disease , nephrectomy , and/or renal transplant . Subject AST ALT &gt; 2 ×ULN TBil &gt; 1.5 × ULN screening , history serious hepatic disease . Subject present symptom dysuria , anuria , oliguria urinary retention . Subject history recurrent urinary tract infection recurrent genital infection ( develop 3 time within 24 week ( 168 day ) prior start screen ) . Subject urinary tract infection genital infection subjective symptom . Subject history angina unstable , myocardial infarction , angioplasty , serious heart disease ( NYHA Class IIIV ) within 24 week ( 168 day ) prior start screening , complication heart disease , investigator 's subinvestigator 's opinion , may interfere evaluation safety ASP1941 . Subject uncontrolled blood pressure ( systolic blood pressure≥160 mmHg diastolic blood pressure≥100 mmHg supine position 5minute rest screening ) . Subject serious gastrointestinal disease history serious gastrointestinal operation . Subject malignant tumor concomitantly ( subject may enrol study subject history malignant tumor recur without treatment within 5 year prior start screen ) . Subject psychiatric disorder make subject unsuitable study participation . Subject drug addiction alcohol abuse . Subject history drug allergy . Subject unable adhere compliance hospital visit dose instruction specify study , agree . Subject donate 400 mL whole blood within 90 day , 200 mL whole blood within 30 day , blood component within 14 day prior start screen . Subject condition , investigator 's subinvestigator 's opinion , make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>type 1 diabetes mellitus</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>